SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Celator Pharmaceuticals, Inc. and The Leukemia & Lymphoma Society Announce Positive Data from Phase 2b Study of CPX-351 at the American Society of Hematology Annual Meeting